Specific Use-Result of Spiriva Respimat® in Asthmatics
NCT03188120 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 193
Last updated 2019-11-27
Summary
The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use
Conditions
Interventions
- DRUG
-
Spiriva Respimat
Drug
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Yukako Ogi · [email protected]
Eligibility
- Min Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-04
- Primary Completion
- 2018-09-22
- Completion
- 2018-11-08
Countries
- Japan
Study Locations
More Related Trials
-
Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients
NCT02182479 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics
NCT01747629 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Albuterol Spiromax® in Subjects With Asthma
NCT01698320 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy
NCT02181335 ·Status: COMPLETED ·Phase: PHASE3
-
A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®
NCT00884689 ·Status: COMPLETED
-
Impact of Tiotropium Add-on Therapy in Patients With Asthma
NCT03964220 ·Status: COMPLETED
-
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
NCT01257230 ·Status: COMPLETED ·Phase: PHASE3
-
Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
NCT01647646 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma
NCT01634113 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study on the Efficacy and Safety of SHR-4597 Inhalant in Adult Patients With Asthma
NCT06940700 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
NCT00652002 ·Status: COMPLETED ·Phase: PHASE3
-
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
NCT00573222 ·Status: COMPLETED
-
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
NCT01397162 ·Status: TERMINATED ·Phase: PHASE2
-
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy
NCT00319306 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children
NCT00569192 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
NCT06261957 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma
NCT00365560 ·Status: COMPLETED ·Phase: PHASE2
-
Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone
NCT01458886 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
NCT01095016 ·Status: COMPLETED ·Phase: PHASE3
-
Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
NCT00255255 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma
NCT02182505 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5
NCT00651651 ·Status: COMPLETED ·Phase: PHASE3
-
Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition
NCT02173795 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia
NCT00939341 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
NCT05850494 ·Status: COMPLETED ·Phase: PHASE3